We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

4 Surging Diagnostics & Research Stocks to Buy in September

1 13 10

While the COVID-19 pandemic highlighted the importance of the diagnostics and research industry, the sector is expected to continue growing due to the rise in chronic diseases and AI-based innovations. So, we think it could be wise to scoop up the shares of quality diagnostics and research stocks Agilent (A), Mettler-Toledo (MTD), Laboratory Corporation of America (LH), and Waters Corporation (WAT). Let’s discuss.

The resurgence of COVID-19 cases across several parts of the world has been driving the diagnosis and research industry’s growth. Furthermore, according to the CDC, six in 10 Americans live with at least one chronic disease, such as heart disease, stroke, cancer, or diabetes. So, rising chronic disorders are expected to boost the industry’s prospects.

Also, the application of artificial intelligence (AI) in the industry is expected to drive further growth. According to a Grand View Research report, the use of AI in the diagnostics market is expected to grow at a 32.8% CAGR over the next seven years.

Given this backdrop, we think it could be wise to bet on fundamentally strong diagnostics and research stocks Agilent Technologies, Inc. (A), Mettler-Toledo International Inc. (MTD), Laboratory Corporation of America Holdings (LH), and Waters Corporation (WAT).

Click here to checkout our Healthcare Sector Report for 2021

Agilent Technologies, Inc. (A)

Operating for more than two decades, A functions primarily through Life Sciences and Applied Markets, the Diagnostics, Genomics, and the Agilent CrossLab segments. In addition, its life sciences and applied markets segment offer application-focused solutions, including instruments and software. A is based in Santa Clara, Calif.

A signed a worldwide distribution agreement with Visiopharm on September 2, enabling it to co-market Visiopharm’s portfolio of CE-IVD marked AI-driven precision pathology software. The agreement is expected to help expand the company’s product portfolio in the growing digital pathology market.

A’s net revenue increased 25.8% year-over-year to $1.59 billion in its fiscal third quarter, ended July 31, 2021. Its income from operations came in at $336 million, up 46.1% year-over-year. While its non-GAAP net income increased 38.7%........

© Entrepreneur

Get it on Google Play